Address: 504, Peninsula TowersPeninsula Corporate ParkGanpatrao Kadam Marg, Lower ParelIND – Mumbai 400 013,India
Tel: +91 22 40 49 11 11
At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients’ needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 talented employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners – we play to our strengths and tap into the organisations with greater or complementary strengths.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Restless Legs Syndrome
Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII)
Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol)
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII)
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April,…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in…
The USD 41 billion Indian pharma industry, the world’s third largest by volume and 13th largest by value, stands…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with…
COVID-19 restrictions have severely hampered multinational pharma companies who rely on India for generics and…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…
The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions…
Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the…